This compound is primarily utilized in the field of medicinal chemistry, particularly in the development of proteolysis-targeting chimeras (PROTACs). It serves as a key component in designing molecules that can selectively degrade target proteins, which is a promising approach for treating various diseases, including cancer. Its structure allows it to bind effectively to E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of specific proteins. Additionally, it has been explored in the synthesis of small molecules for neurodegenerative disease research, where targeted protein degradation can help mitigate pathological protein accumulation. Its bromine substitution further enhances its reactivity, making it a versatile intermediate in organic synthesis for drug discovery.